Latest News
Connected Thinking
Leading Voices
Latest News
Durvalumab Improves Survival in Liver and Biliary Tract Cancers
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Liver cancers including hepatocellular carcinoma (HCC) and biliary tract or bile duct cancers (BTC) are rare but deadly, with only 20% and 9% of the patients surviving at 5 years respectively. In a welcome and much-needed development, studies show that the immunotherapy drug Durvalumab (tradename Imfinzi) […]
Learn MoreA Better Medication For Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma: Zanubrutinib
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. In two large clinical trials, zanubrutinib (tradename Brukinsa) outperformed Ibrutinib and Bendamustine-Rituximab, which are common drugs used as a first treatment for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). This led to its swift approval by the FDA for clinical use in these cancers. […]
Learn MoreZanubrutinib: A Better Medication For Chronic Lymphocytic Leukemias & Small Lymphocytic Lymphomas
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. In two large clinical trials, zanubrutinib (tradename Brukinsa) outperformed Ibrutinib and Bendamustine-Rituximab, two common first-line treatments for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). This led to its swift approval by the FDA for clinical use in the community. Zanubrutinib belongs to a class […]
Learn MoreNew Developments In Tyrosine Kinase Inhibitor Therapy (TKI) for Chronic Myeloid Leukemia (CML)
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Tyrosine Kinase Inhibitors (TKIs) are a highly specific treatment for Chronic Myeloid Leukemia (CML). CML is a type of blood cancer that arises in the cells of the red-spongy tissue lining, called the bone marrow, the insides of large bones. TKIs are a form of targeted […]
Learn MoreDistinguishing Between Acute And Chronic Myeloid Leukemia
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are two types of leukemias or blood cell cancers that originate in the myeloid tissue, commonly known as the bone marrow. Due to certain mutations or changes within the DNA of the bone marrow cells, one or […]
Learn MoreMonitoring Patients During Oral Treatment for CML
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. These days, the standard of care for chronic myeloid leukemia (CML) is a type of targeted therapy known as tyrosine kinase inhibitors (TKIs). When a patient begins this treatment, they need to be monitored regularly to ensure their body is tolerating the drugs. “When someone starts […]
Learn MoreThe Powerful Drugs for Chronic Myeloid Leukemia: Tyrosine Kinase Inhibitors (TKIs)
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Tyrosine Kinase Inhibitors (TKIs) are targeted therapies that have had great success in treating chronic myeloid leukemia (CML). Before these drugs were available, the standard of care of CML was a stem cell transplant, but TKIs have changed the game. “A stem cell transplant (or allogeneic […]
Learn MoreThe Different Phases Of Chronic Myeloid Leukemia & Their Management
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Chronic myeloid leukemia (CML) is a type of blood cancer that is broken up into several different phases. The treatment options available to you will depend on the phase, as well as several other factors. The myeloid tissue, called the bone marrow, is the red spongy […]
Learn More